Form 4: Clene Inc. Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director David J. Matlin was granted stock options for 5,159 shares of Clene Inc. common stock on May 21, 2026.
Summary
- Director David J. Matlin received two separate grants of stock options for Clene Inc. (CLNN) common stock.
- The total number of options granted is 5,159 shares.
- The exercise price for all granted options is $6.81 per share.
- The grants were issued under the Clene Inc. Amended 2020 Stock Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on the company's immediate financial position.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of these options.
Risks
- Market price volatility of CLNN common stock relative to the $6.81 exercise price.
- General risks associated with equity-based compensation plans.
Future Outlook
The options vest either immediately (3,659 shares) or over a 12-month period (1,500 shares) and remain exercisable until May 20, 2036.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to incentivize long-term board oversight and alignment with shareholder value, common in the biotechnology and pharmaceutical sectors.
Comparison to Industry Standards
- The use of the 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotech firms.
- Vesting schedules involving a mix of immediate and time-based vesting are common for board members to ensure retention and ongoing commitment.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 1,500 options in 12 equal monthly installments starting June 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/21/2026 | Date of grant for stock options and earliest transaction date. |
| 05/22/2026 | Date of filing for the Form 4. |
| 06/21/2026 | Beginning of the 12-month vesting period for the 1,500 share option grant. |
| 05/20/2036 | Expiration date for the granted stock options. |
Keywords
Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.